Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To Determine The Efficacy of a Rapid Bolus Injection of Dexmedetomidine on the Incidence of Emergence Agitation in Anesthetized Children and the Cardiovascular Profile of a Rapid Bolus Injection of Dexmedetomidine.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Pittsburgh; Peter Davis
• Collaborators: Hospira, Inc.; Hospira, now a wholly owned subsidiary of Pfizer
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• children undergoing tonsillectomy with and without adenoidectomy and myringotomy and tube insertion

• ASA 1,2,3

• females who have started menses but have a negative urine pregnancy test

Exclusion Criteria:

• patients with known dysrhythmias,

• not recovering in the ICU

• developmental delay,

• autism communication disorder

• bleeding disorder

• PI discretion